MUHC Foundation

Hemostemix Inc. is a clinical-stage biotechnology company based in Calgary, Canada, focused on developing, manufacturing, and commercializing blood-derived cell therapies for various medical conditions. The company specializes in creating cell therapy products from a patient's own blood, providing a minimally invasive source of therapeutic cells. Its lead product, ACP-01, is an autologous cell therapy currently undergoing Phase II clinical trials aimed at treating critical limb ischemia and other ischemic conditions, including peripheral arterial disease and angina. Additionally, Hemostemix is engaged in the development of diverse cell populations, including angiogenic, myocardial, neural, and bone cell precursors, to expand its therapeutic offerings in vascular diseases.